An unclear outlook for Replimune’s BLA resubmission outlook for vusolimogene oderparepvec in advanced melanoma and debated clinical positioning for Arvinas’s vepdegestrant and Boehringer Ingelheim’s survodutide underscore intensifying competition across breast cancer and obesity therapeutics among other major catalysts are expected in Q2 2026, according to GlobalData, a leading intelligence and productivity platform. 

The FDA’s initial rejection of Replimmune’s approval bid for vusolimogene oderparepvec with a complete response letter (CRL) outlining questions on the trial design and patient heterogeneity was unexpected. The FDA later accepted a BLA resubmission with a PDUFA date set for 10 April 2026, which signals a positive outlook on the agency’s stance, while experts interviewed by the Insights news service at GlobalData continue to debate the robustness of the Phase II IGNYTE single-arm data in a PD-1–resistant population lacking a clear comparator.

On the other hand, Arvinas’s drug vepdegestrant demonstrated improved efficacy over fulvestrant in ESR1-mutant ER+/HER2-negative breast cancer in the Phase III VERITAC-2 trial, supporting its potential use as a second-line therapy. However, as per the Insights news service at GlobalData, limited differentiation in the broader ER+/HER2- population and growing competition among oral SERDs may confine its near-term uptake following the upcoming 5 June 2026 PDUFA decision. 

Irena Maragkou, Senior Healthcare Researcher at GlobalData, comments: “Experts say that even though vepdegestrant shows a statistically significant improvement in progression-free survival in ESR1-mutant breast cancer, its clinical positioning is debated given comparable or superior outcomes achieved by existing oral SERDs. As a result, its positioning is likely to be limited to second-line use after SERD failure rather than as a preferred alternative.”

GlobalData’s Catalyst Monitor Q2 2026 Report reveals that vepdegestrant’s global sales are set to reach $193 million in 2034. Arvinas has a market cap of almost $700 million. A detailed analysis of the publicly available data on vepdegestrant, its upcoming approval decision date, and expert insights on other material events is included in the report, which covers a total of 15 significant events that are expected to occur in Q2 2026. 

Some of the catalysts covered in the report, include Johnson & Johnson’s EMA approval for icotrokinra in plaque psoriasis, Phase III trial results for Regenxbio’s Phase III trial results for RGX-202 in Duchenne muscular dystrophy (DMD) and Boehringer Ingelheim’s Phase III trial results for survodutide in obesity.

Boehringer Ingelheim’s survodutide, a dual glucagon/GLP-1 receptor agonist, is being evaluated in Phase III SYNCHRONIZE trials for obesity, which build on Phase II data suggesting the drug’s weight loss efficacy is comparable to leading therapies such as Zepbound from Eli Lilly (NYSE:LLY) and Wegovy from Novo Nordisk (CPH:NOVO-B). Data from the Phase III SYNCHRONIZE-1 study (NCT06066515) is expected to read out in H1 2026.

Maragkou concludes: “The upcoming Phase III readouts will be pivotal in assessing whether survodutide can establish a competitive position within an increasingly crowded obesity treatment landscape, particularly as next-generation therapies, including triple agonists and amylin-based combinations, continue to emerge. Although its efficacy profile appears encouraging, tolerability concerns observed in Phase II, such as higher rates of adverse events and treatment discontinuation, may influence its clinical adoption and positioning.”